Drug Trial Radar · NCT05440383
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
287
Actual
Start
Oct 11, 2022
Primary completion
Aug 21, 2024
Study completion Aug 21, 2024
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, randomized, double-blind, parallel-group study to confirm non-inferiority of KLH-2109 to Leuprorelin acetate in uterine fibroids patient with menorrhagia
Conditions
- Uterine Fibroids (MeSH Heading: Leiomyoma)
Interventions
KLH-2109Drug
Oral administration
LeuprorelinDrug
Subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administrationTime frame: Up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Resarch Site
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.